You are here

Major Research Funders and International NGOs To Implement WHO Standards on Reporting Clinical Trial Results

Agreement aims to make all outcomes—even if negative—“more findable, accessible, and reusable”

Some of the world’s largest funders of medical research and international non-governmental organizations (NGOs) have agreed on new standards that will require all clinical trials they fund or support to be registered, and the results disclosed publicly.

In a joint statement, the Indian Council of Medical Research, the Norwegian Research Council, the UK Medical Research Council, Médecins Sans Frontières and Epicentre (its research arm), PATH, the Coalition for Epidemic Preparedness Innovations (CEPI), Institut Pasteur, the Bill and Melinda Gates Foundation, and the Wellcome Trust agreed to develop and implement policies within the next year that require all trials they fund, cofund, sponsor, or support to be registered in a publicly available registry. They also agreed that all results would be disclosed within specified time frames on the registry and/or by publication in a scientific journal.

Today, about 50% of clinical trials go unreported, according to several studies, often because the results are negative. These unreported trial results leave an incomplete and potentially misleading picture of the risks and benefits of vaccines, drugs, and medical devices, and can lead to use of suboptimal or even harmful products.

“Research funders are making a strong statement that there will be no more excuses on why some clinical trials remain unreported long after they have completed,” said Marie-Paule Kieny, PhD, assistant director-general for health systems and innovation at the World Health Organization (WHO).

The signatories to the statement also agreed to monitor compliance with registration requirements and to endorse the development of systems to monitor how results are reported.

“We need timely clinical trial results to inform clinical care practices as well as make decisions about allocation of resources for future research,” said Soumya Swaminathan, MD, director-general of the Indian Council of Medical Research. “We welcome the agreement of international standards for reporting time frames that everyone can work towards.”

In 2015, the WHO published its position on public disclosure of results from clinical trials, which defines time frames within which results should be reported, and calls for older unpublished trials to be reported. That position builds on the World Medical Association’s Declaration of Helsinki in 2013. Today’s agreement by some of the world’s major research funders and international NGOs will mean the ethical principles described in both statements will now be enforced in thousands of trials every year.

“Requiring summary results of clinical trials to be made freely available through open access registries within 12 months of study completion is good for both science and society,” said Jeremy Farrar, BSc, MBBS, FRCP, DPhil, director of the Wellcome Trust. “Not only will this help ensure that these research findings are more discoverable, but it will also reduce reporting biases, which currently favor publication of trials which have a positive outcome. Today’s statement is in line with Wellcome’s broader ambition to make all research outputs which arise from our funding more findable, accessible, and reusable.”

Most of these trials and their results will be accessible via the WHO’s International Clinical Trials Registry Platform, a global database of clinical trials that compiles data from 17 registries around the world, including the United States’ clinicaltrials.gov, the European Union’s Clinical Trials Register, the Chinese and Indian Clinical Trial Registries and many others.

Source: WHO; May 18, 2017.

More Headlines

New combo is a maintenance treatment for virologically suppressed HIV-1
Researchers find opioid-agonist treatment saves lives and money compared with detox
Tirasemtiv did not differentiate itself from placebo in phase 3 study
Instead of targeting CD19 on the surface of cancer cells, new approach targets CD22
Four in 10 U.S. cases and deaths are linked to risk factors we can change
Approach could help slow growth of antibiotic-resistant bacteria
Needle length and dose target patients weighing 16.5 to 33 pounds
Five sepsis deaths had been reported in late-phase trials
Patients can avoid long drives to distant specialists